A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Effects of Multiple Subcutaneous Injections of Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Reduced Ejection Fraction

Trial Profile

A Phase 2 Randomized, Double-Blinded, Placebo-Controlled Study to Evaluate the Effects of Multiple Subcutaneous Injections of Elamipretide on Left Ventricular Function in Subjects With Stable Heart Failure With Reduced Ejection Fraction

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 04 Dec 2017

At a glance

  • Drugs Elamipretide (Primary)
  • Indications Heart failure
  • Focus Therapeutic Use
  • Acronyms PROGRESS-HF
  • Sponsors Stealth BioTherapeutics
  • Most Recent Events

    • 04 Dec 2017 This trial has been completed in Netherlands, according to European Clinical Trials Database
    • 06 Sep 2017 Status changed from recruiting to active, no longer recruiting.
    • 03 May 2017 Planned number of patients changed from 70 to 66.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top